Targeting treatment options for castration-resistant prostate cancer.

Miller, Dannah R; Ingersoll, Matthew A; Teply, Benjamin A; Lin, Ming-Fong

Miller, Dannah R; Ingersoll, Matthew A; Teply, Benjamin A; Lin, Ming-Fong.

Afiliación

Miller DR; Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center Omaha, Nebraska, United States of America.
Ingersoll MA; Department of Pharmacology, University of Colorado Anschutz Medical Campus Aurora, CO, United States of America.
Teply BA; Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center Omaha, Nebraska, United States of America.
Lin MF; Department of Pharmacology, Creighton University Omaha, Nebraska, United States of America.

Am J Clin Exp Urol ; 9(1): 101-120, 2021.

Article en En | MEDLINE | ID: mdl-33816699

Palabras clave

Prostate cancer; androgen deprivation therapy; castration-resistant prostate cancer; combination treatment; targeting therapy

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Am J Clin Exp Urol Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos